Abstract
Antibodies that potently neutralize highly diverse HIV-1 variants offer great potential for therapy and prevention. Passive administration of HIV-specific neutralizing antibodies genetically modified to have a long serum half-life has now been shown to confer long-lasting protection from infection in the rhesus macaque model.